Showing results (1-10 of 232) with videos related to
Sort By:
Pageof 24
Expert Opinion on Therapeutic Targets|December 4, 2014
MicroRNAs as therapeutic targets in atherosclerosisXavier Loyer, Ziad Mallat, Chantal M Boulanger, et al.Circulation Research|January 18, 2014
Microvesicles as cell-cell messengers in cardiovascular diseasesXavier Loyer, Anne-Clémence Vion, Alain Tedgui, et al.Seminars in Thrombosis and Hemostasis|November 12, 2010
Microparticles: key protagonists in cardiovascular disordersNicolas Amabile, Pierre-Emmanuel Rautou, Alain Tedgui, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 1, 2011
Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot studyNicolas Amabile, Alain P Guérin, Alain Tedgui, et al.Cell and Tissue Research|November 8, 2008
Endothelial microparticles in diseasesGilles N Chironi, Chantal M Boulanger, Alain Simon, et al.Circulation Research|August 20, 2011
Microparticles, vascular function, and atherothrombosisPierre-Emmanuel Rautou, Anne-Clémence Vion, Nicolas Amabile, et al.Circulation Research|March 29, 2013
Shear stress regulates endothelial microparticle releaseAnne-Clémence Vion, Bhama Ramkhelawon, Xavier Loyer, et al.Journal of the American College of Cardiology|February 20, 2007
Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaquesAurélie S Leroyer, Hirotaka Isobe, Guy Lesèche, et al.Vascular Medicine (London, England)|June 1, 2005
The role of inflammation in atherothrombosis: implications for clinical practiceAlain TedguiJournal of the American Society of Nephrology : JASN|September 30, 2005
Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failureNicolas Amabile, Alain P Guérin, Aurélie Leroyer, et al.Pageof 24